Immunovia Completes Analytical Validation of New Cancer Test
Immunovia, a leading pancreatic cancer diagnostics company, has recently completed the analytical validation for its next-generation test aimed at detecting early-stage pancreatic cancer. The company, known for its innovative approaches, has showcased remarkable results throughout its validation process, reinforcing the test's reliability and robustness.
Exceptional Performance of Next-Generation Test
The next-generation test's biomarkers underwent extensive evaluations, yielding impressive outcomes. Comprehensive experiments assessed over 23 key attributes to meet the rigorous guidelines established by the Clinical and Laboratory Standards Institute (CLSI). Under the stewardship of Immunovia's lab director, Lisa Ford, Ph.D., these tests ensured compliance with the Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) accreditation standards. This rigorous testing guarantees that the diagnostic tool meets the highest industry benchmarks.
Validation Highlights
Several significant findings emerged from the analytical validation:
- Precision: The test exhibited high precision and reproducibility across various testing instances, thereby ensuring dependable results.
- Linearity: Accurate results were recorded at different biomarker concentrations.
- Sensitivity: The assay proved to be highly sensitive, allowing the detection of key biomarkers even in low concentrations.
- Stability: Biomarkers maintained their stability under diverse conditions, confirming their integrity and the accuracy of measurements.
- Robustness: The test demonstrated consistent performance across different batches and lab setups, highlighting its robustness.
Advancements in Technology
The analytical validation was accomplished using a state-of-the-art automated ELISA analyzer, enhancing both performance and processing capacity over Immunovia's earlier platforms and typical manual tests. This modern approach reflects Immunovia's commitment to advancing diagnostic technology.
Next Steps for Clinical Validation
With the successful completion of analytical validation, Immunovia is now embarking on a large-scale clinical validation study. This endeavor aims to evaluate the next-generation test's accuracy in identifying stage 1 and 2 pancreatic cancer. Expected to be finalized by December 2024, the study will provide crucial insights into the test's clinical performance, particularly its sensitivity and specificity.
Company Background and Mission
Immunovia AB is dedicated to enhancing survival rates for pancreatic cancer patients by facilitating early detection. The company focuses on developing and commercializing straightforward blood tests that identify proteins and antibodies indicating a high risk of pancreatic cancer. By collaborating with healthcare providers and advocacy groups, Immunovia seeks to make its tests available to individuals at increased risk.
Addressing High-Risk Populations
Currently, the United States stands as the largest market for pancreatic cancer detection. The company estimates that around 1.8 million individuals in the country are at high risk for developing pancreatic cancer and could benefit significantly from routine surveillance testing.
Contact Information
For more information, please reach out to Jeff Borcherding, CEO and President, or Karin Almqvist Liwendahl, Chief Financial Officer.
Frequently Asked Questions
What is the new test developed by Immunovia?
The new test is a next-generation diagnostic tool designed for the early detection of pancreatic cancer.
What are the main highlights of the analytical validation?
Key highlights include high precision, sensitivity, stability, and robustness of the test under various conditions.
How does the new technology differ from previous methods?
The new test utilizes an advanced automated ELISA analyzer, significantly improving performance and throughput compared to older platforms.
What is the timeline for the clinical validation study?
The clinical validation study is expected to be completed by December 2024, providing insights into the test's clinical accuracy.
How does Immunovia support high-risk individuals?
Immunovia collaborates with healthcare providers and advocacy groups to ensure access to testing for high-risk individuals, enhancing early detection opportunities.
